Literature DB >> 27257915

Multidrug Resistance in Non-PCV13 Serotypes of Streptococcus pneumoniae in Northern Japan, 2014.

Mitsuyo Kawaguchiya1, Noriko Urushibara1, Nobumichi Kobayashi1.   

Abstract

Since the implementation of routine PCV13 immunization in Japan, nonvaccine serotypes (NVTs) have been increasing among clinical isolates of Streptococcus pneumoniae. In this study, susceptibility to 18 antibiotics was tested for all the 231 isolates with NVTs, which were collected from children <16 years of age in northern Japan in 2014 (July-November). High resistance rates were observed for macrolides (>90.9%), tetracycline (91.3%), and clindamycin (75.3%), while penicillin (PEN) nonsusceptibility (PNSP; MIC ≥0.12 μg/ml) was detected in 42.9% of the pneumococci [39.4%; PEN-intermediate S. pneumoniae (PISP), 3.5%; PEN-resistant S. pneumoniae (PRSP)]. All serotype 15A isolates were PRSP (MIC, ≥2 μg/ml) or PISP, and PNSP was prevalent in also serotypes 23A (96.9%), 6C (41%), and 35B (33.3%). Overall, 42.0% of the isolates showed multidrug resistance (MDR). Sequence types (STs) determined for 20 PNSP isolates with NVTs were ST63 (15A), STs 242 or 5832 (6C), STs 338 or 5242 (23A), and ST558 (35B). All the PNSP isolates possessed tet(M), and erm(B) or mefA(A/E), and 70% of them were gPRSP having three altered genes pbp1a, pbp2x, and pbp2b. Among alterations in transpeptidase-coding region of penicillin-binding proteins (PBPs), two substitutions of T371S in the STMK motif and TSQF574-577NTGY in PBP1a were common to all PRSP isolates. The present study showed the spread of PNSP in NVTs 15A, 23A, 6C, and 35B, and the emergence of the MDR international clone Sweden15A-ST63 in northern Japan.

Entities:  

Keywords:  Japan; multidrug resistance; non-PCV13 serotypes; penicillin binding proteins; penicillin nonsusceptible pneumococci; serotype 15A

Mesh:

Substances:

Year:  2016        PMID: 27257915     DOI: 10.1089/mdr.2016.0054

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  5 in total

Review 1.  Prevention of Invasive Pneumococcal Disease: Problems Emerged After Some Years of the 13-Valent Pneumococcal Conjugate Vaccine Use.

Authors:  Nicola Principi; Giuseppe Di Cara; Ilaria Bizzarri; Chiara Isidori; Paola Borgia; Costanza Mignini; Marco Saponara; Alberto Argentiero; Susanna Esposito
Journal:  Curr Infect Dis Rep       Date:  2018-01-24       Impact factor: 3.725

2.  Clinical and Bacteriological Analysis of Pediatric Pneumococcal Meningitis after 13-Valent Pneumococcal Conjugate Vaccine Introduction in Japan.

Authors:  Erika Kurihara; Kenichi Takeshita; Saori Tanaka; Noriko Takeuchi; Misako Ohkusu; Haruka Hishiki; Naruhiko Ishiwada
Journal:  Microbiol Spectr       Date:  2022-03-31

3.  Comparison of the Impact of Pneumococcal Conjugate Vaccine 10 or Pneumococcal Conjugate Vaccine 13 on Invasive Pneumococcal Disease in Equivalent Populations.

Authors:  Pontus Naucler; Ilias Galanis; Eva Morfeldt; Jessica Darenberg; Åke Örtqvist; Birgitta Henriques-Normark
Journal:  Clin Infect Dis       Date:  2017-11-13       Impact factor: 9.079

4.  Invasive Serotype 35B Pneumococci Including an Expanding Serotype Switch Lineage, United States, 2015-2016.

Authors:  Sopio Chochua; Benjamin J Metcalf; Zhongya Li; Hollis Walker; Theresa Tran; Lesley McGee; Bernard Beall
Journal:  Emerg Infect Dis       Date:  2017-06       Impact factor: 6.883

5.  Epidemiology of hospitalised paediatric community-acquired pneumonia and bacterial pneumonia following the introduction of 13-valent pneumococcal conjugate vaccine in the national immunisation programme in Japan.

Authors:  N Takeuchi; S Naito; M Ohkusu; K Abe; K Shizuno; Y Takahashi; Y Omata; T Nakazawa; K Takeshita; H Hishiki; T Hoshino; Y Sato; N Ishiwada
Journal:  Epidemiol Infect       Date:  2020-04-17       Impact factor: 2.451

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.